Loader

Pathways

PathWhiz ID Pathway Meta Data

PW128302

Pw128302 View Pathway
drug action

Brexpiprazole Dopamine Agonist Action Pathway

Homo sapiens
Although the exact mechanism of action of brexpiprazole in psychiatric disorders has not been fully elucidated, the efficacy of brexpiprazole may be attributed to combined partial agonist activity at 5-HT1A and dopamine D2 receptors, and antagonist activity at 5-HT2A receptors. Brexpiprazole is predominantly, a 5-HT1A, D2, and D3 partial agonist and a 5-HT2A, 5-HT2B, 5-HT7, alpha1A, alpha1B, alpha1D, and alpha2C antagonist with a chemical formula of 7-{4-[4-(1-Benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one. Brexpiprazole is indicated as adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults. It is also indicated for the treatment of schizophrenia in patients 13 years of age and older. Brexpiprazole is also indicated for the treatment of agitation associated with dementia due to Alzheimer’s disease.

PW145997

Pw145997 View Pathway
drug action

Brexpiprazole Drug Metabolism Action Pathway

Homo sapiens

PW176324

Pw176324 View Pathway
metabolic

Brexpiprazole Predicted Metabolism Pathway

Homo sapiens
Metabolites of sildenafil are predicted with biotransformer.

PW128303

Pw128303 View Pathway
drug action

Brexpiprazole Serotonin Action Action Pathway

Homo sapiens
Although the exact mechanism of action of brexpiprazole in psychiatric disorders has not been fully elucidated, the efficacy of brexpiprazole may be attributed to combined partial agonist activity at 5-HT1A and dopamine D2 receptors, and antagonist activity at 5-HT2A receptors. Brexpiprazole is predominantly, a 5-HT1A, D2, and D3 partial agonist and a 5-HT2A, 5-HT2B, 5-HT7, alpha1A, alpha1B, alpha1D, and alpha2C antagonist with a chemical formula of 7-{4-[4-(1-Benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one. Brexpiprazole is indicated as adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults. It is also indicated for the treatment of schizophrenia in patients 13 years of age and older. Brexpiprazole is also indicated for the treatment of agitation associated with dementia due to Alzheimer’s disease.

PW146508

Pw146508 View Pathway
drug action

Brigatinib Drug Metabolism Action Pathway

Homo sapiens

PW132401

Pw132401 View Pathway
metabolic

Brilliant blue G Drug Metabolism

Homo sapiens
Brilliant blue G is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Brilliant blue G passes through the liver and is then excreted from the body mainly through the kidney.

PW146931

Pw146931 View Pathway
drug action

Brilliant blue G Drug Metabolism Action Pathway

Homo sapiens

PW146338

Pw146338 View Pathway
drug action

Brilliant green cation Drug Metabolism Action Pathway

Homo sapiens

PW144606

Pw144606 View Pathway
drug action

Brimonidine Drug Metabolism Action Pathway

Homo sapiens

PW127462

Pw127462 View Pathway
drug action

Brincidofovir Action Pathway

Homo sapiens
Brincidofovir is an oral lipid prodrug of cidofovir used in the treatment of human smallpox disease. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir. . Brincidofovir is a pro-drug comprising cidofovir conjugated to a lipid molecule - the lipid component mimics an endogenous lipid, lysophosphatidylcholine, which allows the molecule to hijack endogenous lipid uptake pathways to enter infected cells. Following uptake, the lipid molecule is cleaved to generate cidofovir, which is then phosphorylated to generate the active antiviral compound, cidofovir disphosphate. Cidofovir acts through the selective inhibition of viral DNA polymerase. After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to the active metabolite cidofovir diphosphate. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis. Less Viral DNA is transported into the nucleus, therefore, less viral DNA is integrated into the host DNA. Less viral proteins produced, fewer viruses can form.